SCHEMBL5453185

SCHEMBL5453185

NC(=O)c1c(NC(=O)C2CC2)sc2c1CCC(CO)C2

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 1/20 0.65
REV1 Q9UBZ9 2/20 0.63
AIP O00170 1/20 0.58
SGTA O43765 1/20 0.58
TOMM70 O94826 1/20 0.58
STIP1 P31948 1/20 0.58
PPP5C P53041 1/20 0.58
DNAJC7 Q99615 1/20 0.58
STUB1 Q9UNE7 1/20 0.58
TNIK Q9UKE5 1/20 0.53
ALDH1A1 P00352 6/20 0.53
KDM4E B2RXH2 5/20 0.53
HPGD P15428 3/20 0.53
MAPT P10636 4/20 0.51
DUSP3 P51452 1/20 0.51
PTPN5 P54829 1/20 0.51
PTPN11 Q06124 1/20 0.51
RAB9A P51151 4/20 0.51
MEN1 O00255 3/20 0.51
KMT2A Q03164 3/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5447651 1.00 FLT3 (0.65) FLT3REV1AIPSGTATOMM70
SCHEMBL5454136 0.87 REV1 (0.81) FLT3REV1AIPSGTATOMM70
SCHEMBL5451446 0.85 AIP (0.71) FLT3REV1AIPSGTATOMM70
SCHEMBL5453282 0.85 AIP (0.71) FLT3REV1AIPSGTATOMM70
SCHEMBL5455042 0.84 FLT3 (0.70) FLT3REV1AIPSGTATOMM70
SCHEMBL5451302 0.84 FLT3 (0.70) FLT3REV1AIPSGTATOMM70
SCHEMBL8291584 0.83 REV1 (0.61) FLT3REV1AIPSGTATOMM70
SCHEMBL5755697 0.82 FLT3 (0.68) FLT3REV1AIPSGTATOMM70
SCHEMBL3916303 0.82 REV1 (0.79) FLT3REV1ALDH1A1KDM4EHPGD
SCHEMBL5449204 0.82 FLT3 (0.68) FLT3REV1AIPSGTATOMM70

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 EP claimed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 FLT3 3509/4885REV1 1861/4885AIP 3230/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.